Albert David Limited (ALBERTDAVD)

Loading page…

Albert David Limited (ALBERTDAVD) · mywealthgrid

About

Albert David Limited is a pharmaceuticals company with quarterly revenues of ₹70–101 Cr and a market cap of ₹459 Cr, positioning it as a mid-scale player in India's healthcare sector. Promoters hold 62.24% of shares. The most recent quarter (June 2026) reported ₹101.34 Cr in revenue and ₹32 Cr in net profit.

Face value: ₹10

Market cap

₹488 Cr

P/E

21.6×

P/B

1.2×

Dividend yield

0.6%

ROE

-0.4%

ROCE

0.8%

Debt / equity

0.07

OPM

1.6%

EPS (TTM)

₹39.5

Book value

₹685.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Earnings instability: three loss-making quarters (Mar 2025: -₹10.33 Cr, Dec 2024: -₹9.39 Cr, Mar 2026: -₹21.43 Cr) in eight quarters signal inconsistent execution or structural margin vulnerability
Negative ROE of -0.38% despite low debt (D/E 0.07) indicates operational margin or asset-turnover weakness; verify whether recent profit recovery signals structural improvement or cyclical uptick
Thin structural margins: full-year OPM of 1.64% leaves minimal cushion against cost inflation or price competition; investigate why recent quarters show margin spikes (Dec 2025: 12.04%, Jun 2026: 10.51%) but fail to sustain
Pharma sector pricing pressure: generic competition and price controls are persistent; verify the company's therapeutic mix, cost structure, and ability to defend margins

Generated analysis · source review pending

Growth drivers

Revenue expansion: Jun 2026 quarterly revenue of ₹101.34 Cr versus Jun 2025 (₹70.57 Cr, +43% YoY); verify if sustainable and segment-driven
Margin recovery: Jun 2026 OPM of 10.51% and net profit of ₹32 Cr are trailing-eight-quarter peaks; investigate sustainability
Cash generation: five dividend payouts since 2022 (latest July 2026) indicate cash conversion; verify capex plans and reinvestment strategy
Leverage headroom: D/E of 0.07 provides debt capacity for acquisitions or capex to fund growth trajectory

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹856.7-2.2%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0.1)
+High promoter holding of 62.2% with no pledge

Cons

−Low return on equity of 8.6% (3-yr avg)
−Thin operating margin of 1.6%
−Modest revenue growth of 6.2% a year over the last 5 years
−Weak interest coverage of 1.2×

Research score

Structured signal from quality, growth, valuation and momentum.

51/100

Business quality: 20
Growth: 67
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	321	73	73	317	321	247	314	342	362	346	334
COGS	-104	18	18	107	105	86	115	123	126	116	114
Gross profit	—	55	55	210	215	161	199	218	236	229	220
	395	47	47	181	185	142	158	174	189	226	214
	30	8	8	30	30	19	41	44	47	3	5
OPM %	9.4%	11.6%	11.6%	9.4%	9.5%	7.7%	13%	13%	12.9%	0.9%	1.6%
Depreciation	9	1	1	7	8	8	9	9	7	7	10
Interest	2	0	0	1	1	1	1	0	0	0	3
	2	3	3	16	7	17	16	15	58	30	7
Profit before tax	63	9	9	38	29	27	47	51	97	25	1
Tax	15	3	3	11	10	5	12	15	22	8	2
Tax %	23.8%	30.1%	30.1%	29.5%	33.8%	19.3%	25.5%	28.7%	22.5%	31.8%	388.5%
	48	7	7	27	19	22	35	36	75	17	-1
PAT margin %	14.9%	9.1%	9.1%	8.4%	6%	9%	11.3%	10.6%	20.8%	5%	-0.5%
EPS (₹)	84.1	11.6	11.6	46.7	33.6	38.8	61.8	63.4	132.2	30.1	-2.6
EPS adjusted (₹)	—	—	—	—	—	38.8	61.8	63.4	132.1	30.1	-2.6
	6.5%	47.4%	47.4%	12.9%	20.8%	15.5%	14.6%	14.2%	8.7%	16.6%	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	6	6	6	6	6	6
Reserves	239	274	306	377	387	386
	1	5	5	2	10	28
	96	118	106	113	109	99
Total equity & liabilities	341	403	423	498	511	519
	84	88	80	83	99	100
CWIP	1	1	3	7	2	21
Investments	138	183	193	273	261	247
	119	131	148	135	150	152
Total assets	341	403	423	498	511	519

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	66.3%	67.1%	65.2%	63.3%	64%	65.1%	66.4%	65.9%
EBITDA margin %	9.4%	9.5%	7.7%	13%	13%	12.9%	0.9%	1.6%
EBIT margin %	7.2%	7.1%	4.4%	10.2%	10.5%	11%	-1.1%	-1.3%
PAT margin %	8.4%	6%	9%	11.3%	10.6%	20.8%	5%	-0.5%
Working capital
Receivable days	—	—	29	29	32	30	29	37
Inventory days	—	—	151	124	150	126	201	187
Payable days	—	—	135	98	95	98	118	104
NWC days	—	—	45	55	87	57	112	120
Leverage
Current ratio	—	—	2.77	2.33	3.07	3.75	3.4	3.24
Debt to EBITDA	—	—	0.04	0.12	0.12	0.04	3.32	5.22
Debt to equity	—	—	0	0.02	0.02	0.01	0.03	0.07
Interest coverage	47.5	37.2	43.2	90.2	111.3	305	62.5	1.2
Asset turnover	—	—	0.72	0.78	0.81	0.73	0.68	0.64
Return ratios
Return on assets %	—	—	6.5%	8.8%	8.5%	15.1%	3.4%	-0.3%
Return on capital employed %	—	—	10.8%	17.2%	16.6%	27%	6.4%	0.8%
Return on equity %	—	—	9.1%	12.6%	11.6%	19.7%	4.4%	-0.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	62.04%	62.04%	62.13%	62.13%	62.13%	62.13%	62.24%	62.24%	62.24%	62.24%	62.24%	62.24%
	0.57%	0.7%	0.98%	0.8%	0.88%	0.86%	1.01%	0.84%	0.6%	0.6%	0.58%	0.57%
	1.9%	1.67%	1.67%	1.67%	1.64%	1.64%	1.65%	1.66%	1.66%	1.66%	1.66%	1.64%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	35.49%	35.59%	35.22%	35.4%	35.35%	35.37%	35.1%	35.26%	35.5%	35.5%	35.52%	35.55%
No. of shareholders	—	—	—	—	—	—	—	—	14,666	13,967	13,555	13,155

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Albert David Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

61 announcementsExport CSV

22 Sept 2026, 12:43 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

11 Sept 2026, 5:31 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

29 Aug 2026, 3:41 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

7 Aug 2026, 6:28 pmAGM/EGM

Voting Results For The 87Th Annual General Meeting Of The Company.

AGM PDF

7 Aug 2026, 6:18 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

7 Aug 2026, 2:59 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

28 Jul 2026, 1:46 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

24 Jul 2026, 3:52 pmBoard Meeting

Board Meeting Intimation for To Consider, Approve And Take On Record The Unaudited Financial Results Of The Company For The First Quarter Ended On June 30, 2026.

Exchange filing PDF

Date	Category	Subject	Filing
22 Sept 2026, 12:43 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
11 Sept 2026, 5:31 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	66.3%	67.1%	65.2%	63.3%	64%	65.1%	66.4%	65.9%
EBITDA margin %	9.4%	9.5%	7.7%	13%	13%	12.9%	0.9%	1.6%
EBIT margin %	7.2%	7.1%	4.4%	10.2%	10.5%	11%	-1.1%	-1.3%
PAT margin %	8.4%	6%	9%	11.3%	10.6%	20.8%	5%	-0.5%
Working capital
Receivable days	—	—	29	29	32	30	29	37
Inventory days	—	—	151	124	150	126	201	187
Payable days	—	—	135	98	95	98	118	104
NWC days	—	—	45	55	87	57	112	120
Leverage
Current ratio	—	—	2.77	2.33	3.07	3.75	3.4	3.24
Debt to EBITDA	—	—	0.04	0.12	0.12	0.04	3.32	5.22
Debt to equity	—	—	0	0.02	0.02	0.01	0.03	0.07
Interest coverage	47.5	37.2	43.2	90.2	111.3	305	62.5	1.2
Asset turnover	—	—	0.72	0.78	0.81	0.73	0.68	0.64
Return ratios
Return on assets %	—	—	6.5%	8.8%	8.5%	15.1%	3.4%	-0.3%
Return on capital employed %	—	—	10.8%	17.2%	16.6%	27%	6.4%	0.8%
Return on equity %	—	—	9.1%	12.6%	11.6%	19.7%	4.4%	-0.4%

20 deals · 12 Aug 2021 – 29 Aug 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
29 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	29,044	₹1,652.20	₹4.80 Cr
29 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	29,044	₹1,649.18	₹4.79 Cr
26 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	32,513	₹1,553.72	₹5.05 Cr
26 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	32,513	₹1,551.82	₹5.05 Cr
23 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	30,971	₹1,403.65	₹4.35 Cr
23 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	30,971	₹1,409.57	₹4.37 Cr
23 Aug 2024	PARAM CAPITAL	Bulk	NSE	Buy	30,000	₹1,445.60	₹4.34 Cr
25 Jan 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	44,790	₹1,487.46	₹6.66 Cr
25 Jan 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	44,790	₹1,491.90	₹6.68 Cr
3 Jan 2022	XTX MARKETS LLP	Bulk	NSE	Sell	36,139	₹680.89	₹2.46 Cr

1–10 of 20

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	30	32	30	37	40	11	46	-28	-8
	-11	-19	-20	-37	-40	-5	-33	23	-4
	-5	-17	-10	-2	-5	-6	-8	0	12
Net cash flow	14	-4	-0	-2	-4	-1	4	-5	-0
Free cash flow	—	—	—	35	33	5	35	-43	-8
CFO / Operating profit %	353.9%	107.8%	99.8%	191.3%	99%	23.7%	97.1%	-938.6%	-140.3%

Albert David Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Credit ratings

20

1

Compounded sales growth

Return on equity

Albert David Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Announcements

Quarterly record

Annual reports

Credit ratings

Dividends20

Board meetings1

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

20

1